Trial: 201601048

Phase 1 study evaluating combination therapy with the receptor tyrosine kinase inhibitor Pexidartinib (PLX3397) and Sirolimus in patients with unresectable sarcoma and Phase 2 study in malignant peripheral nerve sheath tumors.

Phase

I/II

Principal Investigator

Van Tine, Brian

Disease Site

Bones and Joints; Brain and Nervous System; Soft Tissue

Learn more about this study at: clinicaltrials.gov